$VIRX
Viracta Therapeutics, Inc.

2014 Q1 Form 10-Q Financial Statement

#000119312514187522 Filed on May 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $1.995M $1.989M
YoY Change 0.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.420M $2.440M
YoY Change 40.16% 11.42%
% of Gross Profit
Research & Development $7.552M $7.377M
YoY Change 2.37% 10.93%
% of Gross Profit
Depreciation & Amortization $5.000K $7.000K
YoY Change -28.57% -30.0%
% of Gross Profit
Operating Expenses $10.97M $9.821M
YoY Change 11.69% 11.1%
Operating Profit -$8.974M -$7.832M
YoY Change 14.58%
Interest Expense $547.0K $831.0K
YoY Change -34.18% -359.69%
% of Operating Profit
Other Income/Expense, Net -$5.052M -$2.961M
YoY Change 70.62% -37.92%
Pretax Income -$14.57M -$11.62M
YoY Change 25.39% -16.52%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.57M -$11.62M
YoY Change 25.37% -16.49%
Net Earnings / Revenue -730.48% -584.41%
Basic Earnings Per Share -$0.26 -$0.23
Diluted Earnings Per Share -$0.26 -$0.23
COMMON SHARES
Basic Shares Outstanding 56.31M 51.59M
Diluted Shares Outstanding 56.31M 51.59M

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.70M $61.00M
YoY Change 15.9% 74.79%
Cash & Equivalents $50.35M $12.56M
Short-Term Investments $20.30M $48.50M
Other Short-Term Assets $1.100M $1.200M
YoY Change -8.33% -36.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $71.76M $62.20M
YoY Change 15.36% 69.48%
LONG-TERM ASSETS
Property, Plant & Equipment $41.00K $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $0.00
YoY Change -100.0%
Total Long-Term Assets $74.00K $100.0K
YoY Change -26.0% -50.0%
TOTAL ASSETS
Total Short-Term Assets $71.76M $62.20M
Total Long-Term Assets $74.00K $100.0K
Total Assets $71.83M $62.30M
YoY Change 15.3% 68.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.011M $1.500M
YoY Change -32.6% 66.67%
Accrued Expenses $6.700M $7.300M
YoY Change -8.22% 55.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.300M $8.200M
YoY Change 13.41% 8100.0%
Total Short-Term Liabilities $37.67M $35.90M
YoY Change 4.93% 182.68%
LONG-TERM LIABILITIES
Long-Term Debt $6.700M $15.60M
YoY Change -57.05% 64.21%
Other Long-Term Liabilities $1.700M $9.700M
YoY Change -82.47%
Total Long-Term Liabilities $8.400M $25.30M
YoY Change -66.8% 166.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.67M $35.90M
Total Long-Term Liabilities $8.400M $25.30M
Total Liabilities $46.10M $61.20M
YoY Change -24.67% 175.68%
SHAREHOLDERS EQUITY
Retained Earnings -$494.3M
YoY Change
Common Stock $520.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.76M $1.100M
YoY Change
Total Liabilities & Shareholders Equity $71.83M $62.30M
YoY Change 15.3% 68.83%

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$14.57M -$11.62M
YoY Change 25.37% -16.49%
Depreciation, Depletion And Amortization $5.000K $7.000K
YoY Change -28.57% -30.0%
Cash From Operating Activities -$11.43M -$9.484M
YoY Change 20.55% 1.98%
INVESTING ACTIVITIES
Capital Expenditures $23.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.880M $7.750M
YoY Change -49.94% 47.9%
Cash From Investing Activities $3.854M $7.752M
YoY Change -50.28% 47.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.81M -653.0K
YoY Change -6656.2% -2276.67%
NET CHANGE
Cash From Operating Activities -11.43M -9.484M
Cash From Investing Activities 3.854M 7.752M
Cash From Financing Activities 42.81M -653.0K
Net Change In Cash 35.23M -2.385M
YoY Change -1577.27% -40.82%
FREE CASH FLOW
Cash From Operating Activities -$11.43M -$9.484M
Capital Expenditures $23.00K
Free Cash Flow -$11.46M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60217011 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12555000
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.52
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2169000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1011000
CY2014Q1 us-gaap Notes Payable Current
NotesPayableCurrent
9293000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
37670000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2014Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
12733000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
871000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
25764000
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
520022000
CY2014Q1 us-gaap Notes Payable
NotesPayable
15964000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-494268000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7956000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71829000
CY2014Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
6671000
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1724000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20302000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
71755000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
40492000
CY2014Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
45601000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2014Q1 us-gaap Assets
Assets
71829000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50354000
CY2014Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
45605000
CY2014Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
70700000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2014Q1 snss Cash Equivalents Gross Unrealized Gains
CashEquivalentsGrossUnrealizedGains
CY2014Q1 snss Common Stock Fair Value
CommonStockFairValue
6.61
CY2014Q1 snss Cash Equivalents Estimated Fair Value
CashEquivalentsEstimatedFairValue
25303000
CY2014Q1 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
4.20
CY2014Q1 snss Cash Equivalents Gross Unrealized Losses
CashEquivalentsGrossUnrealizedLosses
CY2014Q1 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2014Q1 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
3637000
CY2014Q1 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675 pure
CY2014Q1 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
25303000
CY2014Q1 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
3032000 shares
CY2014Q1 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
7000
CY2014Q1 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
3000
CY2014Q1 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
20298000
CY2014Q1 snss Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
3000
CY2014Q1 snss Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
7000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14940000
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.52
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1645000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
953000
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9018000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33972000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7931000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1719000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-6184000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473509000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-479695000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7956000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40525000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9025000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3712000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24172000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30758000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2013Q4 us-gaap Assets
Assets
40525000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30755000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1199000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2013Q4 snss Cash Equivalents Gross Unrealized Gains
CashEquivalentsGrossUnrealizedGains
CY2013Q4 snss Common Stock Fair Value
CommonStockFairValue
4.74
CY2013Q4 snss Cash Equivalents Estimated Fair Value
CashEquivalentsEstimatedFairValue
6583000
CY2013Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
2.56
CY2013Q4 snss Cash Equivalents Gross Unrealized Losses
CashEquivalentsGrossUnrealizedLosses
CY2013Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
4750000
CY2013Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
6583000
CY2013Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
3099000 shares
CY2013Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
3000
CY2013Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
6000
CY2013Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
24175000
CY2013Q4 snss Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
6000
CY2013Q4 snss Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
3000
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y9M18D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.608 pure
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.003 pure
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingGross
43000000
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Net
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingNet
40000000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51587000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9484000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17260000 shares
CY2013Q1 us-gaap Revenues
Revenues
1989000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-513000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11645000
CY2013Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8556000
CY2013Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
694000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2961000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7832000
CY2013Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013Q1 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-2852000
CY2013Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-21000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-11624000
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-787000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2444000
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
176000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-653000
CY2013Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
245000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1989000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2385000
CY2013Q1 us-gaap Interest Expense
InterestExpense
831000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1449000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7752000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7377000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
751000
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16308000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
9821000
CY2013Q1 snss License And Other Revenue
LicenseAndOtherRevenue
1989000
CY2013Q1 snss Exchange Gain Loss On Marketable Securities
ExchangeGainLossOnMarketableSecurities
-32000
CY2013Q1 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1109000
CY2013Q1 snss Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
41000
CY2014Q1 dei Trading Symbol
TradingSymbol
SNSS
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
SUNESIS PHARMACEUTICALS INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001061027
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y6M
CY2014Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.560 pure
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56313000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28458000 shares
CY2014Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.003 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11433000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2014Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Significant Estimates and Judgments</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#x2019;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Significant estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting.</p> </div>
CY2014Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q1 us-gaap Revenues
Revenues
1995000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14566000
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12303000
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2261000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5052000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8974000
CY2014Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q1 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-4937000
CY2014Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
7000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-14573000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-848000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3417000
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
116000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42812000
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
599000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1988000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35233000
CY2014Q1 us-gaap Interest Expense
InterestExpense
547000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
58000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3854000
CY2014Q1 snss Line Of Credit Facility Number Of Installments
LineOfCreditFacilityNumberOfInstallments
32 Installment
CY2014Q1 snss License And Other Revenue
LicenseAndOtherRevenue
1995000
CY2014Q1 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7552000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1306000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16180000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
10969000
CY2014Q1 snss Number Of Tranches For Maximum Borrowing
NumberOfTranchesForMaximumBorrowing
2 Tranches
CY2014Q1 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2014Q1 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2014Q1 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1113000
CY2014Q1 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2014Q1 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
4726000
CY2014Q1 snss Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
325000
CY2014Q1 snss Line Of Credit Facility Final Payment
LineOfCreditFacilityFinalPayment
937500
CY2014Q1 snss Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
40022000

Files In Submission

Name View Source Status
0001193125-14-187522-index-headers.html Edgar Link pending
0001193125-14-187522-index.html Edgar Link pending
0001193125-14-187522.txt Edgar Link pending
0001193125-14-187522-xbrl.zip Edgar Link pending
d702989d10q.htm Edgar Link pending
d702989dex311.htm Edgar Link pending
d702989dex312.htm Edgar Link pending
d702989dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g702989tx_pg001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-20140331.xml Edgar Link completed
snss-20140331.xsd Edgar Link pending
snss-20140331_cal.xml Edgar Link unprocessable
snss-20140331_def.xml Edgar Link unprocessable
snss-20140331_lab.xml Edgar Link unprocessable
snss-20140331_pre.xml Edgar Link unprocessable